Prostate Cancer Coverage from Every Angle

Neeraj Agarwal, MD, on Pairing Androgen-Deprivation Therapy With a CYP17 Inhibitor to Treat Metastatic Prostate Cancer

Posted: Wednesday, July 14, 2021

Neeraj Agarwal, MD, of Huntsman Cancer Institute at the University of Utah, discusses the clinical implications of phase III findings from the SWOG S1216 trial, in which the CYP17 inhibitor TAK-700 (also called orteronel) was paired with androgen-deprivation therapy for men with newly diagnosed metastatic hormone-sensitive prostate cancer.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.